Desk›Healthcare› Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
BSE 524804 · NSE AUROPHARMA · ISIN INE406A01037 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹1,631.00
+0.55%
BSE close, 28 August 2026
₹93,844.13 cr
57.5 cr shares · Mid cap
₹44,929.47 cr
as published
36.2× · 4.77×
EPS ₹45.06 · BV ₹341.93
11,171.72 / 2,414.80
₹ cr, as filed
51
12 selected · 24%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -3.0% |
|---|---|
| Against 52-week low | +60.4% |
| Day change | +0.55% |
| Size band | Mid cap |
| Index membership | NIFTY 500 |
Valuation as published by BSE
| Earnings per share | ₹45.06 |
|---|---|
| Price / earnings | 36.20× |
| Price / book | 4.77× |
| Book value — derived, price ÷ P/B | ₹341.93 |
| Return on equity | 13.19% |
| Operating margin | 40.15% |
| Net margin | 26.33% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 13.18%
- ROE as published
- 13.19%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 2,799.51 | 737.22 | 12.75 | 40.15% | 26.33% |
| Mar-26 · Q | 2,786.55 | 692.23 | 11.92 | 35.73% | 24.84% |
| FY25-26 | 11,171.72 | 2,414.80 | 41.58 | 32.78% | 21.62% |
Quarter on quarter
- Revenue, quarter on quarter
- +0.5%
- Net profit, quarter on quarter
- +6.5%
- Operating margin, quarter on quarter
- +442 bps
Disclosure profile 51 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Press Release | 5 |
| Acquisition | 3 |
| Board Outcome | 1 |
| Concall Transcript | 1 |
| Investor Presentation | 1 |
| Restructuring | 1 |
| Selected sub-total | 12 |
| Procedural | |
| Analyst / Investor Meet | 11 |
| General | 11 |
| Newspaper Publication | 6 |
| AGM / EGM | 4 |
| Subsidiary Incorporation | 2 |
| Annual Report | 1 |
| BRSR | 1 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| Trading Window | 1 |
| Procedural sub-total | 39 |
| Total | 51 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
51 filings · 12 selected · busiest 2026-09-11
Filing rhythm · the twelve most recent
2026-09-112026-10-09
SelectedProcedural
Filings
51 in the window · 16 earlier on record
-
9 October 2026 ·
Newspaper Publication
Submission of Notice published in newspapers.
Company Update / Newspaper Publication View filing →
-
5 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Submission of certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
2 October 2026 ·
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
Intimation of completion of acquisition.
Company Update / General View filing →
-
2 October 2026 ·
Acquisition
Intimation of acquisition of a step down subsidiary in USA.
Company Update / Acquisition View filing →
-
1 October 2026 ·
Acquisition
Intimation of allotment of shares by A1 Biochem Labs (India) Private Limted, a step down subsidiary of the Company.
Company Update / Acquisition View filing →
-
30 September 2026 ·
Press Release / Media Release
Submission of press release that is being issued by the Company in connection with launching of ADQUEY in the U.S and Establishes Dedicated Dermatology Business.
Company Update / Press Release / Media Release View filing →
-
29 September 2026 ·
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation of order passed by Appellate Joint Commissioner (ST), Malkajgiri Division, Hyderabad, Telangana.
Company Update / General View filing →
-
24 September 2026 ·
Closure of Trading Window
Intimation of closure of trading window.
Insider Trading / SAST / Closure of Trading Window View filing →
-
21 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation of investor Analyst meet scheduled on 24.09.2026.
Company Update / Analyst / Investor Meet View filing →
-
15 September 2026 ·
Completion Of US FDA Inspection At Unit-II Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company
Submission of completion of US FDA inspection of Unit-II of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
Company Update / General View filing →
-
15 September 2026 ·
Press Release / Media Release
Submission of Press Release that is being issued in connection with receipt of US FDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol , 40 mcg and 80 mcg.
Company Update / Press Release / Media Release View filing →
-
11 September 2026 ·
Completion Of US FDA Inspection At Unit-IV Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company
Intimation of completion of US FDA inspection of Unit-IV of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
Company Update / General View filing →
-
11 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation of investor / analyst meet scheduled on 22.09.2026.
Company Update / Analyst / Investor Meet View filing →
-
11 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation of investor / analyst meet scheduled on 21.09.2026.
Company Update / Analyst / Investor Meet View filing →
-
11 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation of investor / analyst meet scheduled on 17.09.2026.
Company Update / Analyst / Investor Meet View filing →
-
11 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation of investor / analyst meet scheduled on 18.09.2026.
Company Update / Analyst / Investor Meet View filing →
-
11 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Investor / analyst meet scheduled on 17.09.2026.
Company Update / Analyst / Investor Meet View filing →
-
3 September 2026 ·
Newspaper Publication
Submission of notice published in newspapers.
Company Update / Newspaper Publication View filing →
-
1 September 2026 ·
Acquisition
Intimation of incorporation of a new wholly owned subsidiary by the name of Ávogent Lifesciences Private Limited' by Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
Company Update / Acquisition View filing →
-
31 August 2026 ·
Press Release / Media Release (Revised)
Submission of Press Release.
Company Update / Press Release / Media Release (Revised) View filing →
-
28 August 2026 ·
Completion Of US FDA Inspection At Unit-VI Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company
Intimation of completion of US FDA inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
Company Update / General View filing →
-
28 August 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Submission of Voting Results and Scrutinizer's Report of 39th AGM of the Company held on August 27, 2026.
AGM/EGM / AGM View filing →
-
27 August 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Submission of proceedings of 39th Annual General Meeting of the Company held on 27th August, 2026.
AGM/EGM / AGM View filing →
-
25 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Participation in Investor/ Analyst meet held on September 1-2, 2026 in Hong Kong
Company Update / Analyst / Investor Meet View filing →
-
25 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Investor/ Analyst meet scheduled on September 1, 2026.
Company Update / Analyst / Investor Meet View filing →
-
24 August 2026 ·
Completion Of US FDA Inspection At Lannett Company LLC, A Wholly Owned Subsidiary Of Aurobindo Pharma USA, Inc.
Intimation of completion of US FDA inspection at Lannett Company LLC., a wholly owned subsidiary of Aurobindo Pharma, USA Inc.
Company Update / General View filing →
-
21 August 2026 ·
Completion Of US FDA Inspection At Auro Peptides Ltd, A Subsidiary/Business Arm Of The Company.
Intimation of completion of US FDA inspection at Auro Peptides Limited, a subsidiary of the Company.
Company Update / General View filing →
-
17 August 2026 ·
Classification Of US FDA Inspection At Raleigh Plant, North Carolina, Owned By Aurolife Pharma LLC, A Wholly Owned Step-Down Subsidiary Of The Company, As Voluntary Action Indicated (VAI)
Intimation of classification of US FDA inspection at Raleigh Plant, North Carolina, owned by Aurolife LLF, a wholly owned step down subsidiary of the Company, as Voluntary Actioin Indicated (VAI).
Company Update / General View filing →
-
14 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of participation of officials of the Company in investors / analysts meet to be held on August 19, 2026
Company Update / Analyst / Investor Meet View filing →
-
14 August 2026 ·
Unit I Of Eugia Pharma Specialities Ltd. Received A Warning Letter From US FDA
Intimation of receipt of warning letter from US FDA by Unit 1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.
Company Update / General View filing →
-
13 August 2026 ·
Earnings Call Transcript
Submission of transcript of the earning call on the unaudited financial results for the quarter ended June 30, 2026.
Company Update / Earnings Call Transcript View filing →
-
13 August 2026 ·
Acquisition
Intimation of incorporation of a new wholly owned subsidiary.
Company Update / Acquisition View filing →
-
7 August 2026 ·
Newspaper Publication
Submission of copies of notice published by the Company on August 7, 2026 in Business Standard and Nava Telangana regarding special window for re-lodgement of transfer requests of physical shares.
Company Update / Newspaper Publication View filing →
-
7 August 2026 ·
Newspaper Publication
Submission of copies of newspaper advertisements of the financial results of the Company for the first quarter ended June 30, 2026 as published in Business Standard and Nava Telangana on ....
Company Update / Newspaper Publication View filing →
-
6 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of participation by the officials of the Company in the Investor/Analyst Meet to be held on August 11 to 13, 2026 in Singapore & Hong Kong
Company Update / Analyst / Investor Meet View filing →
-
5 August 2026 ·
Restructuring
Intimation of proposal of merger of two wholly owned stepdown subsidiaries with a wholly owned subsidiary.
Company Update / Restructuring View filing →
-
5 August 2026 ·
Press Release / Media Release
Submission of Press Release on financial results of the Company for the first quarter ended June 30, 2026.
Company Update / Press Release / Media Release View filing →
-
5 August 2026 ·
Investor Presentation
Submission of investor presentation.
Company Update / Investor Presentation View filing →
-
5 August 2026 ·
Board Meeting Outcome for Outcome Of The Board Meeting Held On August 5, 2026
The Board of Directors of the Company at its meeting held today, August 5, 2026, has, inter alia, considered and approved: a) the standalone and consolidated Unaudited Financial Results ....
Board Meeting / Outcome of Board Meeting View filing →
-
4 August 2026 ·
Newspaper Publication
Submission of copies of notice published in newspapers.
Company Update / Newspaper Publication View filing →
-
4 August 2026 ·
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Confirmation of dispatch of letter to the shareholders who have not registered their email ids, providing weblink for integrated Annual Report 2025-26.
Company Update / General View filing →
-
3 August 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
Submission of BRSR for FY 2025-26.
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
3 August 2026 ·
Notice Of 39Th Annual General Meeting
Submission of Notice of 39th Annual General Meeting of the Company to be held August 27, 2026.
AGM/EGM / AGM View filing →
-
3 August 2026 ·
Reg. 34 (1) Annual Report.
Submission of Integrated Annual Report 2025-26
Others / Reg. 34 (1) Annual Report View filing →
-
30 July 2026 ·
Newspaper Publication
Submission of copies of notice published in newspapers intimating the shareholders that the 39th AGM of the Company will be held on August 27, 2026.
Company Update / Newspaper Publication View filing →
-
29 July 2026 ·
Intimation Of 39Th Annual General Meeting Of Aurobindo Pharma Limited.
Intimation of 39th Annual General Meeting of Aurobindo Pharma Limited to be held on August 27, 2026.
AGM/EGM / AGM View filing →
-
29 July 2026 ·
Analyst / Investor Meet - Intimation
Intimation of schedule of Earnings Call to be held on August 6, 2026 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the first quarter ended June 30, 2026.
Company Update / Analyst / Investor Meet View filing →
-
27 July 2026 ·
Board Meeting Intimation for Intimation Of Board Meeting.
Aurobindo Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting ....
Board Meeting / Board Meeting View filing →
-
24 July 2026 ·
Press Release / Media Release
Submission of press release that is being issued in connection with signing non exclusive voluntary license agreement with MSD.
Company Update / Press Release / Media Release View filing →
-
23 July 2026 ·
Acquisition
Intimation of acquisition of majority ownership control in A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA.
Company Update / Acquisition View filing →
-
21 July 2026 ·
ANVISA Approval For Curateq Biologics' Biosimilars Manufacturing Facility
Intimation of receipt of ANVISA approval for Biosimilar manufacturing facility of Curateq Biologics Private Limited, a wholly owned subsidiary of the Company.
Company Update / General View filing →
RSS feed for Aurobindo Pharma Ltd · the 50 most recent filings